• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DACLATASVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • DACLATASVIR chembl:CHEMBL2023898 Approved

    Alternate Names:

    DAKLINZA
    EBP-883
    DACLATASVIR
    BMS 790052
    BMS-790052
    EBP 883
    N,N'-[[1,1'-BIPHENYL]-4,4'-DIYLBIS[1H-IMIDAZOLE-5,2-DIYL-(2S)-2,1-PYRROLIDINEDIYL[(1S)-1-(1-METHYLETHYL)-2-OXO-2,1-ETHANEDIYL]]]BISCARBAMIC ACID C,C'-DIMETHYL ESTER
    BMS790052
    DIMETHYL N,N'-(BIPHENYL-4,4'-DIYLBIS{1H-IMIDAZOLE-5,2-DIYL-((2S)-PYRROLIDINE-2,1- DIYL)((1S)-1-(1-METHYLETHYL)-2-OXOETHANE-2,1-DIYL)})DICARBAMATE
    pubchem.compound:25154714
    chemidplus:1009119-64-5
    chembl:CHEMBL2023898
    rxcui:1606218
    drugbank:09102

    Drug Info:

    (0 More Sources)

    Publications:

    Khan AJ et al., 2019, Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy., J Med Virol
    Hézode C et al., 2015, Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study., Gut
  • DACLATASVIR   IFNL4

    Interaction Score: 8.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30431653 25080450


    Sources:
    PharmGKB

  • DACLATASVIR   IFNL3

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30431653 25080450


    Sources:
    PharmGKB FDA

  • PharmGKB: daclatasvir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hézode C et al., 2015, Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study., Gut
    Khan AJ et al., 2019, Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy., J Med Virol

  • ChemblDrugs: chembl:CHEMBL2023898

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Daclatasvir

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21